| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Martha Geoffrey | Chairman and CEO, Director | 710 MEDTRONIC PARKWAY, MINNEAPOLIS | /s/ Patricia Walesiewicz, attorney-in-fact | 30 Jul 2025 | 0001560409 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MDT | Ordinary Shares | Award | $0 | +37.5K | +19.9% | $0.00 | 226K | 28 Jul 2025 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MDT | Performance Share Units | Award | $0 | +93.8K | $0.00 | 93.8K | 28 Jul 2025 | Performance Share Unit | 93.8K | Direct | F3, F4, F5 | ||
| transaction | MDT | Stock Option (Right to Buy) | Award | $0 | +265K | $0.00 | 265K | 28 Jul 2025 | Ordinary Shares | 265K | $91.97 | Direct | F6 |
| Id | Content |
|---|---|
| F1 | Represents restricted stock units that vest 100% on the third anniversary of the date of grant. |
| F2 | Includes 1,693 shares acquired through dividend reinvestment since the last report filed by the reporting person. |
| F3 | Each performance share unit represents a contingent right to receive one share of Medtronic common stock. |
| F4 | Represents performance share units for which certain performance conditions will have been satisfied on April 28, 2028. |
| F5 | The number of shares to be issued in connection with the performance share units ("PSUs") will vary depending on the level of certain performance metrics achieved over a three (3) year performance period. If target performance metrics are achieved, 93,781 shares will be issued. If maximum performance metrics are achieved, 187,562 shares will be issued. If minimum performance metrics are not met, such PSUs may vest at 0 shares. |
| F6 | These options become exercisable at the rate of 25% of the shares granted per year beginning on the first anniversary of grant. |